US comparative effectiveness not a threat to personalised medicine - NEJM view
This article was originally published in Scrip
Executive Summary
Comparative effectiveness research (CER) in the US continues to be attacked from a variety of fronts. But a perspective article published in the NEJM (May 7th, p 1,925), addresses a common argument against CER – that it will thwart progress in personalised medicine.